CYP19A1 and breast carcinoma: Aromatase inhibitors reduce oestradiol by 83–89 % in patients with breast cancer [48–50], whereas researchers in two randomised trials in healthy high-risk women observed a 53–65 % breast cancer risk reduction associated with these drugs during 5 years of follow-up [51, 52].